Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes

Abstract

Serum concentration of soluble thrombomodulin (TM) is thought to be a marker for endothelial damage. Although several studies have reported that serum TM concentrations are increased in patients with diabetes mellitus, there is little information on the physiological function of soluble TM in human plasma. To evaluate the relationship of soluble TM in plasma between coagulation and/or fibrinolysis system in patients with diabetes, we measured plasma soluble TM, protein C activity (a natural anticoagulant induced by thrombin–TM complex), prothrombin F1+2 (a direct marker of thrombin generation), and plasmin–α2-antiplasmin complex (PAP) and D dimer (measures of fibrinolytic activity) in 55 patients with type 2 diabetes mellitus. The plasma concentrations of soluble TM ( P<0.01), protein C activity ( P<0.01), prothrombin F1+2 ( P<0.05), PAP ( P<0.001) and D dimer ( P<0.001) were significantly higher in the diabetic patients than the 48 age-matched control subjects. The plasma concentrations of TM and PAP were obviously increased in patients with diabetic nephropathy. In the diabetic patients, the plasma concentrations of soluble TM were inversely correlated with the protein C activity ( r=−0.43, P<0.005), and were positively correlated with the plasma concentrations of prothrombin F1+2 ( r=0.63, P<0.0001) and the plasma PAP concentrations ( r=0.30, P<0.05). The present study demonstrated that both coagulation and fibrinolysis are enhanced concomitantly in patients with type 2 diabetes mellitus, and that an increase in plasma concentration of soluble TM is associated not only with hypercoagulability but also with enhanced fibrinolysis in diabetic patients.